Related Experiment Video
Updated: Aug 17, 2025
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal
Minyoung Noh1, Yeomyeong Kim1, Haiying Zhang2
1Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
Abstract:
Retinal vascular diseases are the leading cause of blindness worldwide. These diseases have common disease mechanisms including vascular endothelial growth factor (VEGF) signaling, hypoxia, and inflammation. Treatment of these diseases with laser therapy, anti-VEGF injections and/or steroids has significantly improved clinical outcomes. However, these strategies do not address the underlying cause of the pathology and may have harmful side effects. Pathological processes that damage retinal vessels result in vascular occlusion and impairment of the barrier properties of retinal endothelial cells, leading to excessive vascular leakage. Therefore, a new therapeutic approach is needed for the treatment of retinal vascular disease. We were able to confirm that oral administration of CU06-1004, an endothelial dysfunction blocker, inhibited retinal vascular leakage induced by vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). Interestingly, oral administration of CU06-1004 prevented excessive vascular leakage in the diabetic retinopathy model. In addition, CU06-1004 inhibited angiogenesis and confirmed vascular stabilization in the oxygen-induced retinopathy model and laser-induced CNV model. Taken together, CU06-1004 could be a potential therapeutic agent for the treatment of retinal vascular diseases.
Insights
A novel oral drug, CU06-1004, effectively blocks retinal vascular leakage and stabilizes blood vessels. This endothelial dysfunction blocker shows promise for treating blinding retinal vascular diseases by targeting underlying pathology.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Retinal vascular diseases are a primary cause of global blindness.
- Common mechanisms include VEGF signaling, hypoxia, and inflammation, leading to vascular leakage and occlusion.
- Current treatments like laser therapy and anti-VEGF injections have limitations and side effects.
Purpose of the Study:
- To evaluate CU06-1004, an endothelial dysfunction blocker, as a potential therapeutic agent for retinal vascular diseases.
- To investigate its efficacy in inhibiting vascular leakage and stabilizing retinal vasculature.
Main Methods:
- Oral administration of CU06-1004 in preclinical models of retinal vascular disease.
- Assessment of vascular leakage induced by VEGF and Angiopoietin-2 (Ang2).
- Evaluation in diabetic retinopathy, oxygen-induced retinopathy, and laser-induced choroidal neovascularization (CNV) models.
Main Results:
- CU06-1004 significantly inhibited retinal vascular leakage induced by VEGF and Ang2.
- Oral administration prevented excessive vascular leakage in a diabetic retinopathy model.
- The drug inhibited angiogenesis and promoted vascular stabilization in retinopathy and CNV models.
Conclusions:
- CU06-1004 demonstrates potential as a novel oral therapeutic for retinal vascular diseases.
- Its mechanism involves blocking endothelial dysfunction, reducing vascular leakage, and stabilizing blood vessels.
- Further investigation is warranted to establish its clinical efficacy and safety profile.
